Related Party Transactions and Outside Related Director Information

Medicis Pharmaceutical Corporation (MRX)

4/13/2006 Proxy Information

Because of a consulting arrangement (described in “Director Compensation” below), which was terminated effective September 30, 2005, between the Company and Michael A. Pietrangelo, a member of the Company’s Audit Committee from December 2, 2003 through October 6, 2005, the Company’s Audit Committee was not in compliance with Sections 303A.06 and 303A.07 of the Manual from November 17, 2004 through October 6, 2005. In order to correct such noncompliance, effective October 6, 2005, Mr. Pietrangelo resigned from the Company’s Audit Committee.

10/21/2004 Proxy Information

Mr. Pietrangelo would assist and consult with the Company in areas relating to the pharmaceutical industries, and be available for consultation for a minimum of four hours per month, for a monthly consulting fee of $3,333. During the period of his consulting arrangement, Mr. Pietrangelo also received health and life insurance benefits from the Company. These benefits were terminated effective September 30, 2005.

10/21/2003 Proxy Information

Stuart Diamond was Senior Vice President and Chief Financial Officer of Medicis Pharmaceutical Corporation from 1990 to 1995.